Johnson & Johnson will restart shipments of its Covid-19 vaccine to Europe after the continent’s health agency concluded the benefits outweighed the risks even after it identified a “possible link” between the jab and rare blood clots.
The European Medicines Agency said on Tuesday that a rare combination of blood clots and low platelet count should be added to the list of side-effects from the J&J jab. However, it added that the overall benefits of the single-shot vaccine exceeded the risks of these reactions.
J&J said it would resume shipment of 200m vaccine doses to the EU, Norway and Iceland and update its information on the diagnosis and management of the “very rare adverse event”.
您已阅读20%（693字），剩余80%（2748字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。